Medicare GLP-1 Bridge Program Enhances Access to Weight Loss Medications

Recent data from the Gallup National Health and Well-Being Index highlights that 11% of U.S. adults now use GLP-1 medications for weight loss, equating to approximately 40 million people. This notable rise is likely to persist with the newly implemented Medicare initiative aimed at broadening access to these medications. The Medicare GLP-1 Bridge program, effective since July 1, allows Medicare Part D beneficiaries to obtain specific GLP-1 drugs at a monthly cost of $50 through 2027, managed by the U.S. Centers for Medicare & Medicaid Services (CMS).

The Medicare GLP-1 Bridge program addresses existing coverage gaps by including medications like Foundayo, Wegovy, and the Zepbound KwikPen. To qualify, individuals must be at least 18 years old with a body mass index (BMI) of 35 or higher, or a lower BMI with conditions such as high blood pressure or prediabetes. However, those already on GLP-1 medications via Part D or with certain other conditions are not eligible. The program's approvals remain valid until the end of 2027, or until there is a change in medication, with specifics outlined in the CMS fact sheet.

This initiative is part of a broader trend indicating a decrease in national obesity rates, from 39.9% in 2022 to 36.4% projected by 2026, alongside a stabilization in diabetes diagnosis rates since 2023. The Bridge program offers temporary, non-standard Medicare Part D coverage, meaning the $50 copay does not count toward deductibles or out-of-pocket limits and is not eligible for reductions via support programs like Extra Help. For more detailed information, stakeholders can consult resources provided by the CMS.